Group 1: Corporate Investigations and Issues - China Copper Industry Co., Ltd. director Li Lianbing is under investigation for serious violations of discipline and law [3] - Yong'an Pharmaceutical's actual controller and chairman Chen Yong is under investigation and has been detained [6] - Xianju Pharmaceutical received an administrative penalty of 195 million yuan for price-fixing agreements with competitors [10] Group 2: Corporate Transactions and Financial Warnings - AVIC Capital plans to transfer shares of AVIC Xi'an Aircraft Industry Group and AVIC Avionics to its controlling shareholder for 4.067 billion yuan [7] - Jiangsu Wuzhong's stock will be subject to additional risk warnings due to an audit report with no opinion and non-operational fund occupation by related parties [8] - Tianmao Group and Jinlitai are both unable to disclose their periodic reports on time, leading to stock suspensions [10][11] Group 3: Industry Trends and Changes - Several automotive companies, including Li Auto, Xiaomi, NIO, and Xpeng, are shifting their marketing language from "smart driving" to "assisted driving" [21]

Mergers and Acquisitions - Xingye Yinxin plans to acquire Atlantic Tin Company for approximately 4.54 billion RMB, with a total investment of about 0.98 million AUD at a price of 0.24 AUD per share [1] - Electric Power Investment Energy is undergoing an asset restructuring with its actual controller, State Power Investment Corporation, involving the acquisition of Inner Mongolia Baiyin Hua Coal Power equity [2] - Huibo Yuntong intends to purchase control of Baode Computer System Co., Ltd. through a combination of share issuance and cash payment, with details to be disclosed in a restructuring report [3] Share Buybacks and Increases - Kesi Technology plans to repurchase shares worth between 30 million and 50 million RMB, using self-owned funds for employee stock ownership plans or capital reduction [4] - Fuchuang Precision's major shareholder, Shenyang Advanced Manufacturing Technology Industry Co., Ltd., aims to increase its stake in the company by 1.2 billion to 2.4 billion RMB over the next 12 months [5] Regulatory and Compliance Issues - Yong'an Pharmaceutical's actual controller and chairman, Chen Yong, is under investigation and has been detained, with the company monitoring the situation closely [6] - *ST Gongzhi received a notice of termination of listing due to financial reporting issues, including an audit report with no opinion expressed for the 2024 fiscal year [8] - Xianju Pharmaceutical was fined 195 million RMB for engaging in monopolistic practices related to the pricing of dexamethasone phosphate sodium raw materials [9] - *ST Hengli failed to disclose periodic reports within the legal timeframe, leading to potential termination of its stock listing [10] - Tianmao Group also failed to disclose its periodic reports on time, resulting in stock suspension [11]

证券代码：000627 证券简称：天茂集团 公告编号：2025-014 天茂实业集团股份有限公司 股票交易异常波动公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记 载、误导性陈述或重大遗漏。 一、股票交易异常波动情况 天茂实业集团股份有限公司（以下简称："公司"）的股票（证券代码：000627，证券 简称：天茂集团）连续 3 个交易日（4 月 28 日、4 月 29 日、4 月 30 日）收盘价格跌幅偏离 值累计达 20％以上，根据《深圳证券交易所交易规则》的相关规定，属于股票交易异常波动 情形。 二、公司关注并核实的相关情况 针对公司股票异常波动，公司对有关事项进行了核查，有关情况说明如下： 1、经核查，公司前期披露的信息不存在需要更正、补充之处。 2、近期公共传媒未报道可能或已经对本公司股票交易价格产生较大影响的未公开重大信 息。 3、近期公司经营情况及内外部经营环境未发生重大变化。 4、经向公司控股股东、实际控制人询问，截至目前不存在关于公司的应披露而未披露的 重大事项或处于筹划阶段的重大事项。 5、经查询，控股股东、实际控制人在本公司股票交易异常波动期间未买卖本公司股票。 6 ...

证券代码：000627 证券简称：天茂集团 公告编号：2025-013 天茂实业集团股份有限公司 关于首次回购公司股份及回购股份实施完成暨股份变动的公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、误导性 陈述或者重大遗漏。 天茂实业集团股份有限公司（以下简称"公司"）于2024年6月14日召开第九届董事会第 十六次会议、第九届监事会第十六次会议，于2024年7月1日召开2024年第二次临时股东大会， 审议通过了《关于回购公司股份方案的议案》，同意公司使用自有资金以集中竞价交易方式回 购公司部分股份，回购资金总额不低于人民币5,000万元（含），不超过人民币10,000万元（含）， 回购价格不超过人民币3.34元/股（含）。回购期限自股东大会审议通过回购股份方案之日起 12 个月内，具体回购股份的金额和数量以回购结束时实际回购的金额和股份数量为准，所回购的 股份将用于注销以减少公司注册资本。公司已在中国证券登记结算有限责任公司深圳分公司开 立股份回购专用证券账户，并披露了《回购报告书》。具体内容详见公司分别于2024年6月15 日、2024年7月2日和2024年7月9日刊登在《中国证券 ...

证券代码：000627 证券简称：天茂集团 公告编号：2025-012 天茂实业集团股份有限公司 关于无法在法定期限内披露定期报告暨股票停牌的公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、误导 性陈述或者重大遗漏。 特别提示： 1、天茂实业集团股份有限公司（以下简称"公司"）原定于2025年4月29日披露2024 年年度报告和2025年第一季度报告。因公司定期报告涉及的部分信息需要进一步核实、补 充完善，公司未能完成2024年年报的编制工作，公司无法在法定期限内（2025年4月30日） 披露上述定期报告。 根据《深圳证券交易所股票上市规则》的规定： 1、公司无法在法定期限内披露2024年年度报告，公司股票在定期报告披露期限届满后 次一交易日（2025年5月6日）开市起被实施停牌。 2、若在公司股票停牌两个月内仍无法披露2024年年度报告，公司股票将被实施退市风 险警示。 2、根据《深圳证券交易所股票上市规则》第9.4.1条规定：上市公司未在法定期限内 披露年度报告，且在公司股票停牌两个月内仍未披露，将被实施退市风险警示。根据第 9.4.18条规定：上市公司因触及上述情形其股票交易被 ...

Core Viewpoint - Tianmao Group announced that it is unable to disclose its annual report for 2024 within the statutory deadline due to the need for further verification and completion of certain information [1] Group 1: Company Announcement - The company has not completed the preparation of its 2024 annual report, leading to the inability to disclose it on time [1] - As a result, the company's stock will be suspended from trading starting May 6, 2025 [1] - If the company fails to disclose the 2024 annual report within two months of the stock suspension, it will face a delisting risk warning [1] Group 2: Delisting Risk - Should the delisting risk warning be implemented and the company still does not disclose more than half of the board's assurance of the report's authenticity, accuracy, and completeness within two months, the company's stock will be terminated from listing [1]

Core Viewpoint - Tianmao Group has faced significant stock price declines and concerns regarding its financial reporting, particularly the delay in disclosing its 2024 annual report and 2025 Q1 report, which has raised alarms in the capital market [3][5][6]. Financial Performance - Tianmao Group's 2024 performance forecast indicates a net loss of between 500 million to 750 million yuan, with a projected revenue of 40 billion to 43 billion yuan [5][6]. - The company has reported a staggering 1619.92% increase in claims payments, amounting to 21.822 billion yuan for the first three quarters of 2024, alongside a 23.8% year-on-year decline in first-quarter revenue, which was approximately 11.59 billion yuan [6][8]. Stock Market Reaction - Following the announcement of the reporting delays, Tianmao Group's stock price was locked at the daily limit down of 3.04 yuan per share on April 29, 2024, and remained under pressure with a total market capitalization shrinking to 13.54 billion yuan [3][5]. - The stock had previously experienced significant volatility, including a 200% increase over three months, peaking at 5.42 yuan per share, driven by speculative trading [10]. Corporate Governance and Control - Tianmao Group's primary business is derived from Guohua Life Insurance, with 99.99% of its revenue coming from this segment. The company is controlled by Liu Yiqian, who also chairs both Tianmao Group and Guohua Life [4][10]. - The company has faced challenges in its restructuring efforts, including a failed merger with Guohua Life that was announced in 2019 but ultimately terminated in 2020 [11]. Regulatory Environment - The company has indicated that failure to disclose its annual report within the legal timeframe could lead to a trading suspension of up to two months, and potential delisting risks if compliance is not met [6][8].

Group 1 - In March, the bond market issued a total of 8.74 trillion yuan in various bonds, with government bonds accounting for 1.28 trillion yuan, local government bonds 978.8 billion yuan, and financial bonds 1.02 trillion yuan [1] - The total custody balance of the bond market reached 183.1 trillion yuan by the end of March, with 161.8 trillion yuan in the interbank market and 21.3 trillion yuan in the exchange market [1] - The increase in bond underwriting business may boost the income expectations of brokerage investment banks, while the surge in local government bonds could accelerate the funding pace for infrastructure projects [1] Group 2 - The People's Bank of China held a meeting to implement the overall statistical system for the financial "Five Major Articles," emphasizing the importance of data governance and quality management [2] - Financial institutions are required to enhance their data governance capabilities, which may lead to industry differentiation, with new energy and technology sectors receiving more precise financing support [2] - This initiative aims to solidify the achievements of financial supply-side reforms and provide structural policy guidance for the capital market, ultimately optimizing the financial support framework for economic transformation [2] Group 3 - On April 29, the People's Bank of China conducted a 7-day reverse repurchase operation of 3.405 trillion yuan, maintaining the operation rate at 1.50% [3] - The net injection of 120 billion yuan on that day helps maintain reasonable liquidity and stabilizes the funding environment for sectors sensitive to capital, such as infrastructure and consumption [3] - The neutral and slightly loose liquidity in the interbank market is favorable for bond market allocation demand and creates a stable funding environment for the capital market [3] Group 4 - Tianmao Group announced a delay in the release of its 2024 annual report and 2025 Q1 report due to the need for further information, which may not be disclosed by the legal deadline [4] - Following the announcement, Tianmao Group's stock price fell to 3.04 yuan per share, resulting in a total market value decrease to 15 billion yuan [4] - The insurance sector may face a restructuring of valuation systems, with companies relying on short-term financial products potentially under pressure [4] Group 5 - The offshore yuan strengthened against the US dollar, breaking the 7.27 mark, with a peak of 7.2647 during the trading session [5] - The stability of the yuan exchange rate may enhance foreign investment interest in yuan-denominated assets, particularly in consumer blue chips and high-dividend stocks [6] - Increased demand for liquidity management in the interbank market may arise from the active cross-border capital flows [6]

每经记者 涂颖浩 每经编辑 张益铭 4月29日，天茂集团一字板跌停。截至当日收盘，公司股价报3.04元/股，总市值缩水至150亿元。 当日，天茂集团公告称，原定于2025年4月29日披露的2024年年报和2025年一季报，因定期报告涉及的 部分信息需要进一步补充提供，公司无法在2025年4月29日披露2024年年报和2025年一季报，也可能无 法在法定期限内（2025年4月30日）披露上述定期报告。 天茂集团主要通过控股子公司国华人寿和华瑞保险从事保险业务，保险业务相关的营业收入占到公司主 营业务收入99.99%，是公司的核心业务。 根据该公司此前披露的2024年度业绩预告，未经审计的业绩数据显示，2024年，天茂集团预计全年营收 为400亿元至430亿元。盈利数据显示，公司预计净利润为负值，其中归属于上市公司股东的净利润为亏 损5亿元至7.5亿元，扣非净利润为亏损5.03亿元至7.53亿元，较上年亏损幅度有所收窄。 对于业绩亏损的原因，天茂集团在业绩预告中称，2024年，利率市场环境持续走低，公司控股子公司国 华人寿受750日移动平均国债收益率曲线下行影响，增加计提准备金，尽管国华人寿通过持续优化产品 结构 ...

经济观察报记者姜鑫 国华人寿成立于2007年11月，总部位于上海市，注册地是湖北省武汉市，注册资本为48.46亿元，是由 原中国保险监督管理委员会批准设立的全国性、股份制专业寿险公司。截至2023年末，国华人寿的总资 产近3000亿元。 2025年1月25日，国华人寿的母公司天茂集团发布2024年业绩预告称，预计2024年公司实现归属于上市 公司股东净利润亏损5.00亿元至7.50亿元，上年同期为亏损6.52亿元。 就业绩出现亏损的原因，天茂集团表示，2024年，利率市场环境持续走低，公司控股子公司国华人寿受 750日移动平均国债收益率曲线下行影响，增加计提准备金，尽管国华人寿通过持续优化产品结构、提 升新业务价值、降低负债成本等措施尽可能减少上述不利影响，但仍无法全部抵消增提准备金带来的影 响，从而造成亏损。 4月29日，天茂集团以跌停价开盘。截至收盘，天茂集团被150万手卖单封于跌停，收于3.04元。 根据《深圳证券交易所股票上市规则》相关规定，上市公司未在法定期限内披露年度报告或者半年度报 告，且在公司股票停牌两个月内仍未披露，将被实施退市风险警示。 2019年，天茂集团开始吸收合并国华人寿，同时剥离化 ...